Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 14/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.45 |
| ▸ | FBP1 | P09467 | 5/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836489 | 0.88 | ENPP1 (0.56) | ENPP1EGFR | |
| SCHEMBL2836608 | 0.83 | EGFR (0.60) | ENPP1EGFR | |
| SCHEMBL13969805 | 0.76 | ENPP1 (0.59) | ENPP1EGFRERBB2FBP1ERBB4 | |
| SCHEMBL8812445 | 0.75 | ENPP1 (0.58) | ENPP1EGFRERBB2FBP1ERBB4 | |
| SCHEMBL13091000 | 0.75 | ENPP1 (0.58) | ENPP1EGFRERBB2FBP1ERBB4 | |
| SCHEMBL1013257 | 0.75 | ENPP1 (0.88) | ENPP1EGFRERBB2FBP1ERBB4 | |
| SCHEMBL27866063 | 0.73 | ENPP1 (0.56) | ENPP1EGFRERBB2FBP1ERBB4 | |
| Hydrochloric Acid SCHEMBL2835708 | 0.72 | ENPP1 (0.55) | ENPP1EGFRERBB2FBP1ERBB4 | |
| SCHEMBL4744821 | 0.72 | EGFR (0.55) | EGFRERBB2 | |
| SCHEMBL24393297 | 0.71 | ENPP1 (0.70) | ENPP1EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | claimed |
| EP-2220054-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | Natco Pharma Limited (IN) | 2010-08-25 | — | — | EP | claimed |
| WO-2009057139-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-05-07 | — | — | WO | claimed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | ENPP1 2315/4885EGFR 1213/4885ERBB2 535/4885 |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | ENPP1 2397/4885EGFR 1110/4885ERBB2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.